Cargando…

Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides

Therapeutic oligonucleotides are often modified using the phosphorothioate (PS) backbone modification which enhances stability from nuclease mediated degradation. However, substituting oxygen in the phosphodiester backbone with sulfur introduce chirality into the backbone such that a full PS 16-mer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Østergaard, Michael E, De Hoyos, Cheryl L, Wan, W Brad, Shen, Wen, Low, Audrey, Berdeja, Andres, Vasquez, Guillermo, Murray, Susan, Migawa, Michael T, Liang, Xue-hai, Swayze, Eric E, Crooke, Stanley T, Seth, Punit P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Chemical Biology and Nucleic Acid Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038945/ https://www.ncbi.nlm.nih.gov/pubmed/31980820 http://dx.doi.org/10.1093/nar/gkaa031

Ejemplares similares

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
por: Wan, W. Brad, et al.
Publicado: (2014)

Site-specific incorporation of 5′-methyl DNA enhances the therapeutic profile of gapmer ASOs
por: Vasquez, Guillermo, et al.
Publicado: (2021)

Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
por: Schmidt, Karsten, et al.
Publicado: (2017)

Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
por: Prakash, Thazha P, et al.
Publicado: (2019)

Acute hepatotoxicity of 2′ fluoro-modified 5–10–5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins
por: Shen, Wen, et al.
Publicado: (2018)

Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides
por: Yoshida, Tokuyuki, et al.
Publicado: (2022)

Controlled sulfur-based engineering confers mouldability to phosphorothioate antisense oligonucleotides
por: Genna, Vito, et al.
Publicado: (2023)

Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates
por: Østergaard, Michael E, et al.
Publicado: (2019)

Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals
por: Seth, Punit P, et al.
Publicado: (2012)

Intratracheally administered LNA gapmer antisense oligonucleotides induce robust gene silencing in mouse lung fibroblasts
por: Shin, Minwook, et al.
Publicado: (2022)

G-rich motifs within phosphorothioate-based antisense oligonucleotides (ASOs) drive activation of FXN expression through indirect effects
por: Wang, Feng, et al.
Publicado: (2022)

Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins
por: Migawa, Michael T, et al.
Publicado: (2019)

Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2′-O-methyl gapmer oligonucleotides
por: Valentin, Roxane, et al.
Publicado: (2021)

Nucleoside alpha-thiotriphosphates, polymerases and the exonuclease III analysis of oligonucleotides containing phosphorothioate linkages
por: Yang, Zunyi, et al.
Publicado: (2007)

Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile
por: Hegarty, John P, et al.
Publicado: (2016)

The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA
por: Vickers, Timothy A., et al.
Publicado: (2015)

Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy
por: Watt, Andrew T., et al.
Publicado: (2020)

Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology in vivo
por: Jahns, Hartmut, et al.
Publicado: (2021)

The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration
por: Jafar-nejad, Paymaan, et al.
Publicado: (2020)

Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists
por: Alharbi, Arwaf S, et al.
Publicado: (2020)

Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay
por: Gaus, Hans J, et al.
Publicado: (2019)

RNase H sequence preferences influence antisense oligonucleotide efficiency
por: Kiełpiński, Łukasz J., et al.
Publicado: (2017)

Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides
por: Relizani, Karima, et al.
Publicado: (2021)

Control of backbone chemistry and chirality boost oligonucleotide splice switching activity
por: Kandasamy, Pachamuthu, et al.
Publicado: (2022)

Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers
por: Subramanian, Romesh R., et al.
Publicado: (2015)

Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice
por: Hagedorn, Peter H, et al.
Publicado: (2018)

Single-molecule optical mapping of the distribution of DNA phosphorothioate epigenetics
por: Wei, Yue, et al.
Publicado: (2021)

Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model
por: Sheng, Lei, et al.
Publicado: (2020)

Effects of combinations of gapmer antisense oligonucleotides on the target reduction
por: Yanagidaira, Mitsugu, et al.
Publicado: (2023)

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
por: Swayze, Eric E., et al.
Publicado: (2007)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization
por: Kamola, Piotr J., et al.
Publicado: (2015)

In vitro and in vivo properties of therapeutic oligonucleotides containing non-chiral 3′ and 5′ thiophosphate linkages
por: Duschmalé, Jörg, et al.
Publicado: (2020)

Sulfur-centered hemi-bond radicals as active intermediates in S-DNA phosphorothioate oxidation
por: Jie, Jialong, et al.
Publicado: (2019)

Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines
por: Linnane, Emily, et al.
Publicado: (2019)

Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2018)

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
por: Bailey, Jeffrey K., et al.
Publicado: (2017)

Identification of metabolically stable 5′-phosphate analogs that support single-stranded siRNA activity
por: Prakash, Thazha P., et al.
Publicado: (2015)

The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy
por: Biscans, Annabelle, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g01s4p2rshbvi8uefac1lbkaru